Biohaven prices $175 million public offering at $7.50 per share

Biohaven Ltd. (NYSE: BHVN) announced the pricing of its underwritten public offering of 23,333,334 common shares at $7.50 per share. The biopharmaceutical company granted underwriters a 30-day option to purchase up to an additional 3.5 million shares at the same price, less underwriting discounts and commissions.

The gross proceeds from the offering are expected to reach approximately $175 million before deducting underwriting discounts, commissions, and offering expenses. The offering is expected to close on November 13, 2025, subject to customary closing conditions.

Biohaven stated it intends to use the net proceeds for general corporate purposes. The company describes itself as a global clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare and common diseases.

J.P. Morgan, Goldman Sachs & Co. LLC, Leerink Partners, TD Cowen, and Cantor are serving as book-running managers for the offering. The shares are being issued under an effective shelf registration statement on Form S-3 filed with the Securities and Exchange Commission.

The offering is being conducted through a prospectus supplement and accompanying prospectus available from the underwriters' offices. Biohaven is headquartered in New Haven, Connecticut.

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• Jupiter Neurosciences prices $2M registered direct offering of shares
• Aveanna Healthcare prices secondary offering at $11.75 per share